Does Race Affect the Long-Term Survival Benefit of Systemic Therapy in Pancreatic Adenocarcinoma?

Introduction-Pancreatic Adenocarcinoma (PDAC) is increasingly viewed as a systemic disease. There are known disparities in PDAC outcomes by race. As chemotherapy regimens have developed, the use of systemic therapy is now a key component in the management of PDAC, often in combination with surgical resection. Socioeconomic variables have been linked to variations in outcomes in patients with PDAC; we sought to investigate if race impacted survival in patients who underwent systemic therapy in combination with resection for PDAC.